NP613675.RAIvoc 1KZGce1w islqXvURHIuvRfytXtlo qSWH5nCM
has assertion: NP613675.RAIvoc 1KZGce1w islqXvURHIuvRfytXtlo qSWH5nCM130 assertion
has provenance: NP613675.RAIvoc 1KZGce1w islqXvURHIuvRfytXtlo qSWH5nCM130 provenance
has publication info: NP613675.RAIvoc 1KZGce1w islqXvURHIuvRfytXtlo qSWH5nCM130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:46:23+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP613675.RAIvoc 1KZGce1w islqXvURHIuvRfytXtlo qSWH5nCM130 assertion
type: Assertion
description: [We compared the frequency of FLT3-length mutations (FLT3-LM), FLT3-TKD, MLL-partial tandem duplications (MLL-PTD), NRAS, and KITD816 in 381 patients with MDS refractory anemia with excess blasts [RAEB] n=49; with ringed sideroblasts [RARS] n=310; chronic monomyelocytic leukemia [CMML] n=22) and in 4130 patients with AML (de novo: n=3139; secondary AML [s-AML] following MDS: n=397; therapy-related [t-AML]: n=233; relapsed: n=361).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/17550846
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0